Corcept Therapeutics (CORT) Receives Media Sentiment Rating of 0.13

Marco Green
December 7, 2017

BNP Paribas Arbitrage SA now owns 9,707 shares of the biotechnology company's stock valued at $115,000 after purchasing an additional 9,388 shares during the period. Growth Lp holds 2.70M shares. Starbucks Corp now has $84.53B valuation. PhaseRx, Inc. has 13.95 million shares outstanding, and in the last trade has seen ATR around 0.18. Morgan Stanley (NYSE:MS) has risen 57.08% since December 5, 2016 and is uptrending. It has underperformed by 4.22% the S&P500.

Corcept Therapeutics Incorporated (CORT) revenue scored 19.4% growth from the previous quarter, coming up with $42.46 million. Stock's twelve month price oscillated between $20.77 and $6.70. About 976,291 shares traded. Corcept Therapeutics Incorporated (NASDAQ:CORT) has risen 124.81% since December 5, 2016 and is uptrending. CORT has lost -10.93% in the 1-month period. We have $17.77 PT which if reached, will make NASDAQ:CORT worth $78.00M more.

Investors sentiment increased to 2.43 in 2017 Q2. Its down 0.21, from 1.09 in 2017Q1.

Several hedge funds and other institutional investors have recently modified their holdings of the company. 36 funds opened positions while 61 raised stakes. Fincl Bank Of New York Mellon Corp stated it has 926,350 shares. The firm's revenue for the quarter was up 96.8% on a year-over-year basis. equities analysts predict that Corcept Therapeutics Incorporated will post 0.47 EPS for the current year. Manufacturers Life Ins The accumulated 181,414 shares. Convergence Inv Prns Limited Liability, a Wisconsin-based fund reported 111,231 shares. Corcept Therapeutics earned a media sentiment score of 0.13 on Accern's scale. Moore Management Lp holds 100,000 shares or 0.04% of its portfolio. Whittier Of Nevada holds 293 shares or 0% of its portfolio. Quantbot Techs Ltd Partnership invested in 0.02% or 14,248 shares. Massmutual Trust Co Fsb Adv stated it has 845 shares or 0% of all its holdings. Sg Americas Securities Ltd Llc holds 0% or 9,255 shares.

About Corcept Therapeutics Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Piper Jaffray Companies set a $30.00 price objective on shares of Corcept Therapeutics and gave the stock a "buy" rating in a research report on Tuesday, October 31st. During the same period previous year, the business posted $0.02 earnings per share.

Among 4 analysts covering Corcept Therapeutics (NASDAQ:CORT), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Corcept Therapeutics has $25.0 highest and $14 lowest target. (PE) price hitting a mean target of $38.36 a share, meaning the stock still has potential that could lift the price another 51.38% Also, the recent close suggests the stock is underpriced by 128.89% compared to the most bullish target.

Receive News & Ratings for Corcept Therapeutics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics Incorporated and related companies with our FREE daily email newsletter. The stock has "Buy" rating by Piper Jaffray on Wednesday, October 11. Atlantic Securities downgraded the stock to "Underweight" rating in Wednesday, February 3 report. The company now has a consensus rating of "Hold" and an average target price of $18.20. The stock has "Buy" rating by Ladenburg Thalmann on Thursday, February 2. TheStreet upgraded Corcept Therapeutics from a "c+" rating to a "b" rating in a research report on Friday, March 10th.

Since June 14, 2017, it had 0 insider buys, and 1 insider sale for $606,300 activity. Its up 0.34, from 0.87 in 2017Q1. It turned negative, as 71 investors sold MS shares while 297 reduced holdings. 104 funds opened positions while 473 raised stakes. However, its trading capacity stayed around 1.46 million shares in normal days. Tfs Capital Limited Liability holds 10,692 shares. Cs Mckee Lp holds 273,780 shares. Corporate insiders own 33.30% of the company's stock. Virginia-based Virginia Retirement Et Al has invested 0% in Corcept Therapeutics Incorporated (NASDAQ:CORT).

Consonance Capital Management Lp, which manages about $513.80M and $848.70 million US Long portfolio, decreased its stake in Clovis Oncology Inc (NASDAQ:CLVS) by 789,624 shares to 544,843 shares, valued at $51.01 million in 2017Q2, according to the filing. Qs Investors Ltd Liability Com reported 1,013 shares. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. Therefore 59% are positive. Starbucks Corporation had 80 analyst reports since July 28, 2015 according to SRatingsIntel. The company was maintained on Wednesday, June 28 by Bernstein. The company was initiated on Tuesday, April 5 by Evercore. The rating was maintained by Stifel Nicolaus on Friday, November 3 with "Buy". The firm has "Hold" rating by Argus Research given on Friday, February 10. The firm earned "Neutral" rating on Thursday, July 30 by Guggenheim. They expect this year's earnings to fall -59564.3% year-over-year, followed by 0% decline in the next year. SBUX's profit will be $811.00 million for 26.06 P/E if the $0.57 EPS becomes a reality. Total debt to equity ratio of the company for most recent quarter is 0 whereas long term debt to equity ratio for most recent quarter is 0.

Other reports by Click Lancashire

Discuss This Article